Gemini Gets Green Light for Prediction Markets in the US
Gemini receives CFTC license to launch prediction markets for US customers.
Already have an account? Sign in.
Gemini receives CFTC license to launch prediction markets for US customers.
Despite the massive demand boost, analysts remain cautious, citing the company’s $4.9 billion net loss last year and concerns over valuation.
The delay is due to manufacturing issues at a third-party facility, with no safety or clinical data concerns.
Ardelyx shares fell after losing a court case on Xphozah Medicare coverage, moving drug into bundled payments, hurting revenue outlook.